222 related articles for article (PubMed ID: 18319715)
1. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
Bianco R; Garofalo S; Rosa R; Damiano V; Gelardi T; Daniele G; Marciano R; Ciardiello F; Tortora G
Br J Cancer; 2008 Mar; 98(5):923-30. PubMed ID: 18319715
[TBL] [Abstract][Full Text] [Related]
2. The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Dragowska WH; Weppler SA; Qadir MA; Wong LY; Franssen Y; Baker JH; Kapanen AI; Kierkels GJ; Masin D; Minchinton AI; Gelmon KA; Bally MB
BMC Cancer; 2011 Oct; 11():420. PubMed ID: 21961653
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
4. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
[TBL] [Abstract][Full Text] [Related]
6. Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
Gelardi T; Caputo R; Damiano V; Daniele G; Pepe S; Ciardiello F; Lahn M; Bianco R; Tortora G
Br J Cancer; 2008 Aug; 99(3):473-80. PubMed ID: 18665191
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Morelli MP; Cascone T; Troiani T; Tuccillo C; Bianco R; Normanno N; Romano M; Veneziani BM; Fontanini G; Eckhardt SG; De Pacido S; Tortora G; Ciardiello F
J Cell Physiol; 2006 Aug; 208(2):344-53. PubMed ID: 16688779
[TBL] [Abstract][Full Text] [Related]
8. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG
Biochem Pharmacol; 2009 Sep; 78(5):460-8. PubMed ID: 19427302
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells.
El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
Sci Rep; 2020 Apr; 10(1):6367. PubMed ID: 32286420
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Benavente S; Huang S; Armstrong EA; Chi A; Hsu KT; Wheeler DL; Harari PM
Clin Cancer Res; 2009 Mar; 15(5):1585-92. PubMed ID: 19190133
[TBL] [Abstract][Full Text] [Related]
11. The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
D'Amato V; Rosa R; D'Amato C; Formisano L; Marciano R; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fusciello C; Veneziani BM; De Placido S; Bianco R
Br J Cancer; 2014 Jun; 110(12):2887-95. PubMed ID: 24823695
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Herberger B; Berger W; Puhalla H; Schmid K; Novak S; Brandstetter A; Pirker C; Gruenberger T; Filipits M
Mol Cancer Ther; 2009 Jun; 8(6):1547-56. PubMed ID: 19509244
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Kim HP; Han SW; Kim SH; Im SA; Oh DY; Bang YJ; Kim TY
Mol Cancer Ther; 2008 Mar; 7(3):607-15. PubMed ID: 18347147
[TBL] [Abstract][Full Text] [Related]
16. Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Castillo-Pichardo L; Dharmawardhane SF
Nutr Cancer; 2012; 64(7):1058-69. PubMed ID: 23061908
[TBL] [Abstract][Full Text] [Related]
17. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Weekes CD; Song D; Arcaroli J; Wilson LA; Rubio-Viqueira B; Cusatis G; Garrett-Mayer E; Messersmith WA; Winn RA; Hidalgo M
Neoplasia; 2012 Aug; 14(8):690-701. PubMed ID: 22952422
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Schmid K; Bago-Horvath Z; Berger W; Haitel A; Cejka D; Werzowa J; Filipits M; Herberger B; Hayden H; Sieghart W
Br J Cancer; 2010 Aug; 103(5):622-8. PubMed ID: 20683448
[TBL] [Abstract][Full Text] [Related]
19. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatment combinations: integrating therapy into clinical practice.
Wong ST
Am J Health Syst Pharm; 2009 Dec; 66(23 Suppl 6):S9-S14. PubMed ID: 19923318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]